Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan E Bates

Showing results (101-110 of 293) with videos related to

Pageof 30
Sort By:
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 31, 2008
Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2Suneet Shukla, Robert W Robey, Susan E Bates, et al.
Chemico-Biological Interactions|June 18, 2017
Reversal of ABCB1 mediated efflux by imatinib and nilotinib in cells expressing various transporter levelsPetr Mlejnek, Petr Kosztyu, Petr Dolezel, et al.
Cancer Journal (Sudbury, Mass.)|October 15, 2009
Stable disease is not preferentially observed with targeted therapies and as currently defined has limited value in drug developmentTatiana Vidaurre, Julia Wilkerson, Richard Simon, et al.
Biochemistry|July 19, 2006
The calcium channel blockers, 1,4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2Suneet Shukla, Robert W Robey, Susan E Bates, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2006
Challenges of evaluating the cardiac effects of anticancer agentsSusan E Bates, Douglas R Rosing, Tito Fojo, et al.
Molecular and Cellular Biology|June 25, 2008
Regulation of ABCG2 expression at the 3' untranslated region of its mRNA through modulation of transcript stability and protein translation by a putative microRNA in the S1 colon cancer cell lineKenneth K W To, Zhirong Zhan, Thomas Litman, et al.
The Lancet. Oncology|January 5, 2024
Mitotane and the myth of 14 mg/LMatthew I Ehrlich, Brian W Labadie, Susan E Bates, et al.
The Oncologist|June 7, 2024
Variants of uncertain significance in precision oncology: nuance or nuisance?George S Mellgard, Zoey Atabek, Meredith LaRose, et al.
Anti-Cancer Agents in Medicinal Chemistry|December 30, 2010
ABC transporters: unvalidated therapeutic targets in cancer and the CNSRobert W Robey, Paul R Massey, Laleh Amiri-Kordestani, et al.
Chemmedchem|November 13, 2007
Multispecificity of drug transporters: probing inhibitor selectivity for the human drug efflux transporters ABCB1 and ABCG2Joerg Cramer, Stephan Kopp, Susan E Bates, et al.
Pageof 30

Showing results (101-110 of 293) with videos related to

Sort By:
Pageof 30
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 31, 2008
Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2Suneet Shukla, Robert W Robey, Susan E Bates, et al.
Chemico-Biological Interactions|June 18, 2017
Reversal of ABCB1 mediated efflux by imatinib and nilotinib in cells expressing various transporter levelsPetr Mlejnek, Petr Kosztyu, Petr Dolezel, et al.
Cancer Journal (Sudbury, Mass.)|October 15, 2009
Stable disease is not preferentially observed with targeted therapies and as currently defined has limited value in drug developmentTatiana Vidaurre, Julia Wilkerson, Richard Simon, et al.
Biochemistry|July 19, 2006
The calcium channel blockers, 1,4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2Suneet Shukla, Robert W Robey, Susan E Bates, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2006
Challenges of evaluating the cardiac effects of anticancer agentsSusan E Bates, Douglas R Rosing, Tito Fojo, et al.
Molecular and Cellular Biology|June 25, 2008
Regulation of ABCG2 expression at the 3' untranslated region of its mRNA through modulation of transcript stability and protein translation by a putative microRNA in the S1 colon cancer cell lineKenneth K W To, Zhirong Zhan, Thomas Litman, et al.
The Lancet. Oncology|January 5, 2024
Mitotane and the myth of 14 mg/LMatthew I Ehrlich, Brian W Labadie, Susan E Bates, et al.
The Oncologist|June 7, 2024
Variants of uncertain significance in precision oncology: nuance or nuisance?George S Mellgard, Zoey Atabek, Meredith LaRose, et al.
Anti-Cancer Agents in Medicinal Chemistry|December 30, 2010
ABC transporters: unvalidated therapeutic targets in cancer and the CNSRobert W Robey, Paul R Massey, Laleh Amiri-Kordestani, et al.
Chemmedchem|November 13, 2007
Multispecificity of drug transporters: probing inhibitor selectivity for the human drug efflux transporters ABCB1 and ABCG2Joerg Cramer, Stephan Kopp, Susan E Bates, et al.
Pageof 30